Your arteries age too. The walls grow stiffer, the lining responds less well to the signals that tell it to relax, and blood flow becomes a little less efficient every decade. Some of that change traces back to a small population of cells that have stopped dividing but refuse to leave. A plant pigment called fisetin is being studied as a way to clear those cells. In mice, it works. In people, we don't know yet. Here's what the science actually says.
Why Aging Arteries Matter
Vascular aging is one of the quietest drivers of age-related disease. Long before a heart attack or a stroke, the arteries themselves change. They stiffen. The inner lining, called the endothelium, loses some of its ability to widen on demand. Blood pressure creeps up. The whole system works harder for the same output.
This matters because stiff, poorly responsive arteries are tied to most of the conditions people fear as they age: heart disease, kidney decline, and cognitive problems linked to reduced blood flow in the brain. If you could slow vascular aging, you might slow several diseases at once.
That's the appeal behind a growing line of research into cellular senescence and the blood vessels. And it's why a supplement called fisetin, which most people have never heard of, keeps showing up in longevity conversations.
What Fisetin Actually Is
Fisetin is a flavonoid, a class of plant compounds that give fruits and vegetables their color. You already eat it. Strawberries have the most, followed by apples, persimmons, onions, and cucumbers. The amounts in food are small, far below the doses used in research.
For most of its scientific life, fisetin was studied as a general antioxidant, one of hundreds of plant compounds with mild effects in a test tube. That changed in 2018.
A team at the Mayo Clinic, led by Matthew Yousefzadeh and James Kirkland, tested ten flavonoids to see which ones could selectively kill senescent cells. Senescent cells are cells that have stopped dividing but stay alive and metabolically active, leaking inflammatory signals into the tissue around them. They accumulate with age and are now considered one of the hallmarks of aging.
Fisetin was the most potent of the ten. In the same study, giving fisetin to old mice late in life extended both their lifespan and their healthspan, the portion of life spent in good health. The compound reduced senescence markers across multiple tissues.
That 2018 paper is the reason fisetin moved from "generic antioxidant" to "candidate senolytic." A senolytic is a drug or compound that clears senescent cells. The word combines "senescence" and "lytic," meaning to break apart.
The Vascular Evidence
The 2018 study looked at the whole animal. A 2024 study in the journal Aging Cell zoomed in on the arteries.
Researchers led by Sophia Mahoney at the University of Colorado Boulder gave old mice fisetin on an intermittent schedule: one week on, two weeks off, then one week on again. They were testing the idea that senescent cells could be cleared in short bursts rather than with constant dosing.
The results were specific and measurable. The fisetin-treated old mice had better endothelium-dependent dilation, which is the artery's ability to widen when it should. They also had lower arterial stiffness. One week after the final dose, the researchers found less vascular cell senescence and less of the inflammatory secretion that senescent cells produce, known as the senescence-associated secretory phenotype, or SASP.
The mechanism mattered as much as the result. The improvement came with more nitric oxide available in the vessel wall. Nitric oxide is the molecule that tells arteries to relax, so more of it means better blood flow. The treated mice also showed less oxidative stress, both in the cells generally and in their mitochondria specifically.
A 2025 follow-up extended the picture to muscle. Using the same intermittent approach, fisetin improved physical function and reduced senescence in the skeletal muscle of aging mice. The researchers compared it directly to genetic removal of senescent cells and to synthetic senolytic drugs, and fisetin held up reasonably well against both.
So the animal story is fairly consistent. Short bursts of fisetin clear senescent cells, lower inflammation, and improve how arteries and muscles work in old mice.
The Hit-and-Run Idea
One reason fisetin is interesting is how it seems to work. The Mayo researchers described it as a hit-and-run mechanism.
The thinking goes like this. Senescent cells are a small, fixed problem at any given moment. You don't need a drug circulating in the body all the time. You need to clear the cells, then stop. The cells take time to build back up, so you can dose intermittently, wait, and dose again.
This is different from how most supplements are sold, which is "take it every day forever." If the hit-and-run model holds in humans, the right protocol might be a few days of dosing every month or two, not a daily pill. The mouse studies that worked best used exactly this kind of on-off schedule.
It's an elegant idea. It's also still an idea. No human study has confirmed that intermittent fisetin clears senescent cells in people and produces a lasting benefit.
What We Don't Know
Here is where honesty matters more than enthusiasm.
The human trials haven't reported. The Mayo Clinic has run pilot trials of fisetin in older adults, including a study in women aged 70 to 90 looking at frailty, inflammation, and bone markers. These are small, early studies designed to test safety and feasibility, not to confirm whether fisetin extends healthspan.
As of now, the field is still waiting on clear published outcomes. Until those land, the human case for fisetin rests on mouse data and mechanism, not on results in people.
Absorption is a real problem. Fisetin is poorly absorbed when swallowed. Much of an oral dose never reaches the bloodstream at a meaningful concentration. This is why researchers are testing delivery tricks like liposomal encapsulation, which wraps the compound in fat droplets to improve uptake.
A 2025 cell study using liposome-encapsulated fisetin found it could blunt the inflammatory behavior of senescent cells, an effect researchers call senomorphic. But that's a long way from a capsule on a shelf working in your body.
The cell-study results are mixed. When researchers induce senescence in endothelial cells using the chemotherapy drug doxorubicin, fisetin's effects are inconsistent. Some studies report that fisetin blocks this kind of senescence in vessel-lining cells. Others find no effect in different endothelial cell lines. That inconsistency is a signal that fisetin's senolytic action depends heavily on cell type and on how the senescence was triggered. It's not a universal eraser of old cells.
Supplements are not standardized. Fisetin sold online is an unregulated supplement. Purity, dose, and label accuracy vary between brands. The doses used in research, often calculated per kilogram of body weight in mice, do not translate cleanly to a human capsule.
How to Think About It
If you're a science-minded person watching this space, a few things are worth holding onto.
The biology is genuinely promising. Clearing senescent cells is one of the more credible ideas in aging research, and fisetin is one of the better-studied natural candidates. The vascular data in mice is specific, mechanistic, and repeated.
But "promising in mice" and "proven in humans" are separated by a wide gap that the longevity supplement market routinely pretends doesn't exist. Most marketing for fisetin is years ahead of the evidence. The compound has not been shown to improve artery function, reduce frailty, or extend healthspan in any completed, published human trial.
If you're considering fisetin, the honest position is this: it's plausible, it's being seriously studied, and it's not proven. Talk to your doctor before starting it, especially if you take medications or have a heart condition, since fisetin can interact with drug-metabolizing enzymes. This article is for understanding the science, not for replacing medical advice.
The most reliable things you can do for your arteries today are still the unglamorous ones. Regular aerobic exercise directly improves endothelial function and nitric oxide availability, the same pathway fisetin acts on in mice, and it has decades of human evidence behind it. Fisetin may eventually earn a place alongside those basics. It hasn't yet.
Frequently Asked Questions
Has fisetin been shown to slow aging in humans? No. The strong evidence is in mice. Fisetin clears senescent cells and improves artery and muscle function in aged mice, but no completed human trial has shown it slows aging or improves health outcomes in people. Human studies are underway and have not yet reported clear results.
How is fisetin different from quercetin? Both are flavonoids and both have been tested as senolytics. In the 2018 Mayo Clinic study that screened ten flavonoids, fisetin was the most potent senolytic, outperforming quercetin. Quercetin is more often used in combination with the drug dasatinib in senolytic research, while fisetin has been studied on its own.
What does "hit-and-run" dosing mean? It refers to giving fisetin in short bursts rather than daily. The idea is that senescent cells are a small, slowly rebuilding problem, so you clear them, stop dosing, and repeat weeks later. The mouse studies that worked best used this on-off schedule, but it has not been validated in humans.
Can I just eat strawberries instead? Strawberries are the richest dietary source of fisetin, but the amounts in food are far below the doses used in research. Eating fruit is good for you for many reasons, but you can't reach research-level fisetin doses through diet alone.
Is fisetin safe? Short-term studies in animals and small human pilots have not flagged major safety problems, but long-term safety in healthy adults is unknown. Fisetin can affect drug-metabolizing enzymes, so it may interact with medications. Talk to your doctor before taking it.
Sources
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). "Fisetin is a senotherapeutic that extends health and lifespan." EBioMedicine, 36, 18-28. PubMed: 30279143
- Mahoney SA, Venkatasubramanian R, Darrah MA, et al. (2024). "Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence." Aging Cell, 23(3), e14060. DOI: 10.1111/acel.14060
- Mahoney SA, Clayton ZS, et al. (2025). "Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging." PubMed: 40437670
- Mayo Clinic. "Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults (AFFIRM)." ClinicalTrials.gov. NCT03430037
- Kirkland JL, Tchkonia T, et al. (2024). "Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases." Mechanisms of Ageing and Development. ScienceDirect
- "Targeting Cellular Senescence with Liposome-Encapsulated Fisetin: Evidence of Senomorphic Effect." (2025). International Journal of Molecular Sciences, 26(15), 7489. MDPI
Funding Transparency
LSD is editorially independent. We receive no funding from pharmaceutical, supplement, or longevity companies. In the interest of full transparency, here are the funding and conflict relationships behind the research cited above:
- Sources #1 and #5 (Mayo Clinic senolytic program): Several researchers behind this work, including James Kirkland and Tamara Tchkonia, have disclosed financial interests and hold patents related to senolytic therapies. This does not invalidate the science, but readers should know the lead investigators have a commercial stake in senolytics succeeding.
- Source #2 (Aging Cell, 2024): This vascular study was supported primarily by United States National Institutes of Health and National Institute on Aging grants, which are public funding sources without a direct commercial interest in fisetin.
- General: Fisetin is sold as a commercial supplement by multiple companies. None of the studies cited here were funded by fisetin supplement manufacturers based on the disclosures we reviewed.
Related Reading
- Cellular Senescence: The Science of Zombie Cells - The biology of the cells fisetin is designed to clear, and why they matter for aging.
- Mitochondrial Health and Aging - The oxidative stress pathway that fisetin appears to act on in aging arteries.
- Inflammation and Aging - How the inflammatory signals from senescent cells drive age-related disease.
- Zone 2 Cardio and Longevity - The proven, human-tested way to improve endothelial function and nitric oxide availability.
- The Supplement Landscape - How to think about longevity supplements when the marketing runs ahead of the evidence.
This article is for education, not medical advice. Fisetin is an experimental supplement with no proven benefit in humans. Talk to your doctor before starting any supplement, especially if you take medications or have a heart condition.
Written with the help of AI tools, shaped and verified by humans who care about getting this right.